# Neoadjuvant Chemoradiation With 5-FU(or Capecitabine) and Oxaliplatin Combined With Hyperthermia in Rectal Cancer

> **NCT01716949** · PHASE1,PHASE2 · UNKNOWN · sponsor: **University of Erlangen-Nürnberg Medical School** · enrollment: 59 (estimated)

## Conditions studied

- Rectal Cancer

## Interventions

- **RADIATION:** Radiotherapy
- **PROCEDURE:** Hyperthermia
- **DRUG:** 5-Fluorouracil
- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT01716949
- **Lead sponsor:** University of Erlangen-Nürnberg Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-09
- **Primary completion:** 2022-06
- **Final completion:** 2023-06
- **Target enrollment:** 59 (ESTIMATED)
- **Last updated:** 2017-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01716949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01716949, "Neoadjuvant Chemoradiation With 5-FU(or Capecitabine) and Oxaliplatin Combined With Hyperthermia in Rectal Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01716949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*